Trials / Unknown
UnknownNCT04110093
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
The Efficacy and Safety of Regorafenib Plus PD-1 Inhibitor as Third-line Therapy in Advanced Colorectal Cancer Patients
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Shanghai Changzheng Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is intended to evaluate efficacy and safety of the combination of regorafenib and nivolumab as third-line or later therapy in patients with microsatellite stable (MSS) colorectal cancer (CRC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib and PD-1 inhibitor | All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w). |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
- First posted
- 2019-10-01
- Last updated
- 2020-12-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04110093. Inclusion in this directory is not an endorsement.